FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology. In order to express the transgene exclusively in muscle cells to create an adeno-associated virus using an expression vector containing a muscle-specific promoter C5-12, repeating DNA sequences, complementary to the mir-142 and mir-499 microRNA arms sequences, and a packaging plasmid which contains the C5-tataless promoter and human subtype 2 VP3 virus protein, which contains the additional amino acid sequence TGASSLNIAGLS, for the VP3 virus expression.
EFFECT: invention provides preparing viruses for highly targeted and safe expression of target proteins in muscle tissue.
1 cl, 3 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF RECOMBINANT AAV AND USE THEREOF | 2015 |
|
RU2738421C2 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| DOUBLE-STRANDED RNA CAPABLE OF REDUCING EXPRESSION OF MUTANT ALLELE C.607G>A OF HUMAN GNAO1 GENE | 2022 |
|
RU2816137C1 |
| AMPLIFIER AGENTS TO INCREASE CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION | 2018 |
|
RU2802520C2 |
| VECTORS CONTAINING SPACER/FILLER POLYNUCLEOTIDE SEQUENCES, AND METHODS OF USING THEM | 2014 |
|
RU2725813C2 |
| GENETIC MAKE-UPS FOR ANTI-HIV THERAPY | 2010 |
|
RU2426788C1 |
| AAV-BASED HUNTINGTON'S DISEASE TREATMENT | 2017 |
|
RU2749971C2 |
| CODON-OPTIMIZED NUCLEIC ACID WHICH ENCODES SMN1 PROTEIN, AND USE THEREOF | 2020 |
|
RU2742837C1 |
| RECOMBINANT ADEN-ASSOCIATED VIRUS, WHICH IS HYBRID OF AAV9 AND AAVrh74 SEROTYPES, WITH REDUCED TROPISM FOR LIVER TISSUE | 2019 |
|
RU2812279C2 |
| CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED-END DNA VECTORS (ceDNA) | 2019 |
|
RU2816871C2 |
